Mutation detection in Croatian patients with familial hypercholesterolemia

Ivan Pećin1, Ros Whittall, Marta Futema

  • 1Department of Internal Medicine, University Hospital Center Zagreb, Croatia.

Annals of Human Genetics
|November 8, 2012
PubMed

Insights

Genetic analysis identified causative mutations in 88% of familial hypercholesterolemia (FH) patients, revealing novel variants and highlighting genetic diversity in Croatia for improved diagnosis and prevention of heart disease.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Familial hypercholesterolemia (FH) is a genetic disorder leading to premature heart disease.
  • Mutations in LDLR, APOB, or PCSK9 genes cause FH.
  • Accurate genetic diagnosis is crucial for patient treatment and cascade screening of relatives.

Purpose of the Study:

  • To identify causative genetic mutations in clinically diagnosed Familial hypercholesterolemia patients.
  • To evaluate the utility of High-Resolution Melting (HRM) analysis for FH mutation screening.
  • To investigate the spectrum of genetic variants in FH patients from Croatia.

Main Methods:

  • DNA analysis of eight unrelated FH patients.
  • High-Resolution Melting (HRM) for LDLR, APOB, and PCSK9 genes.
  • Sanger sequencing, predictive algorithms, and MLPA for variant analysis.

Main Results:

  • Identified three novel pathogenic LDLR variants (p.(S470C), p.(C698R), c.2312-2A>C).
  • Confirmed previously reported mutations in LDLR and identified a pathogenic APOB variant (p.(R3527Q)).
  • Causative mutations were found in 88% of patients; no PCSK9 variants or large LDLR deletions/insertions were detected.

Conclusions:

  • High-Resolution Melting (HRM) is an effective screening method for FH mutations.
  • Significant allelic heterogeneity exists in Croatian FH patients.
  • Genetic identification enables targeted treatment and preventative strategies for FH.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Point and Frameshift Mutations01:30

Point and Frameshift Mutations

Point mutations are genetic alterations involving the change of a single nucleotide base pair in DNA. Depending on how the alteration affects protein synthesis, they can lead to various consequences.Point mutations fall into the following types:Silent mutations occur when a nucleotide change does not alter the amino acid sequence due to the redundancy of the genetic code. For instance, changing ACC to ACA still encodes threonine, leaving the protein function unaffected. This occurs because...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...